Direct and indirect effects of epoietin alpha in an experimental model of thrombosis and bleeding in the rabbit;Étude des effets directs et indirects de l'érythropoï étine dans un modèle expérimental de thrombose et de saignement chez le lapin

Annales Francaises d'Anesthesie et de Reanimation

Volumn 22, Issue 10, 2003, Pages 870-878

  Tourreau, S Pham ^a   Fattorutto, M ^a   Bonnin, P ^b   Mazoyer, E ^a   Raphael M ^a   Morin, F ^a   Cupa, M ^a   Samama, C M ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Arterial thrombosis; Bleeding; Erythropoietin; Rabbit; Transfusion

Indexed keywords

ARACHIDONIC ACID; FIBRINOGEN; RECOMBINANT ERYTHROPOIETIN; THROMBOPLASTIN;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CELL COUNT; BLOOD FLOWMETRY; BLOOD PRESSURE MONITORING; BODY TEMPERATURE; CAROTID ARTERY FLOW; COMPRESSION; CONTROLLED STUDY; CYCLIC FLOW REDUCTION; DOSE TIME EFFECT RELATION; DRUG MECHANISM; EAR IMMERSION; ERYTHROCYTE TRANSFUSION; HEART RATE; HEMATOCRIT; HEMOSTASIS; HEPATOSPLENIC BLEEDING; IMMERSION; LUNG VENTILATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; RABBIT; THROMBOCYTE AGGREGATION; THROMBOSIS; ANIMAL; BLOOD FLOW; BLOOD PRESSURE; CAROTID ARTERY; DRUG EFFECT; HEMOBILIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BLEEDING TIME; BLOOD PRESSURE; BODY TEMPERATURE; CAROTID ARTERIES; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; FIBRINOGEN; HEART RATE; HEMOBILIA; HEMORRHAGE; PARTIAL THROMBOPLASTIN TIME; PLATELET AGGREGATION; RABBITS; REGIONAL BLOOD FLOW; THROMBOSIS;

EID: 0345601914     PISSN: 07507658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annfar.2003.08.007     Document Type: Article

References (33)

1. Erslev AJ. Erythropoietin. N Engl J Med 1991;324:1339-44.
2. Bricard H. Erythropoïétine en anesthésie réanimation. Ann Fr Anesth Réanim 1996;15:1152-4.
3. Janvier G, Roth C, Bénillan N, Fialon P, Berty A, Puntous M. Transfusions en chirurgie: peuvent-elles encore être réduites par l'érythropoïétine humaine recombinante ? Ann Fr Anesth Réanim 1996;15:1219-29.
4. Folts JD. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991;83(Suppl IV):3-14.
5. Folts JD, Crowell EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54:365-70.
6. Samama CM, Bonnin P, Bonneau M, Pignaud G, Mazoyer E, Bailliart O, et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Thromb Haemost 1992;68: 500-5.
7. Stephen R, Harker L. Baboon models of acute arterial thrombosis. Thromb Haemost 1987;58:801-5.
8. Golino P, Ragni M, Cirillo P, D'Andrea D, Ravera M, Calabro P, et al. Effect of recombinant active site-blocked activated factor VII in rabbit models of carotid stenosis and myocardial infarction. Blood Coag Fibrinol 2000;11:S149-58.
9. Ouaknine-Orlando B, Samama CM, Riou B, Bonin P, Guillosson JJ, Beaumont JL, et al. Role of the hematocrit in a rabbit model of arterial thrombosis and bleeding. Anesthesiology 1999;90:1454-61.
10. Michelson AD, Mac Gregor H, Barnard MR, Kestin AS, Rohrer MJ, Valeri CR. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost 1994;71:633-40.
11. Moia M, Vizzoto L, Cattaneo, Mannucci PM, Casati S, Ponticelli C. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin. Lancet 1987;28:1227-9.
12. Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, et al. Prevention of thrombosis in patients on haemodialysis by low-dose aspirin. N Engl J Med 1979;301:577-9.
13. Martino MA, Vogel KM, O'Brien SP, Kerstein MD. Erythropoietin therapy improves graft potency with no increased incidence of thrombosis or thrombophlebitis. J Am Coll Surg 1998;187:616-9.
14. Standage BA, Schuman ES, Ackerman D, Gross GF, Ragsdale JW. Does the use of erythropoietin in haemodialysis patients increase dialysis graft thrombosis rates? Am J Surg 1993;165:650-3.
15. Wolf RF, Gilmore LS, Friese P, Downs T, Burstein SA, Dale GL. Erythropoietin potentiates thrombus development in a canine arteriovenous shunt model. Thromb Haemost 1997;77:1020-4.
16. Wolf RF, Peng J, Friese P, Gilmore LS, Burstein SA, Dale GL. Erythropoietin administration increases production and reactivity of platelets in dogs. Thromb Haemost 1997;78:1505-9.
17. Van Geet C, Van Damme-Lombaerts R, Vanrusselt M, Mol A, Proesmans W, Vermylen J. Recombinant human erythropoietin increases blood pressure, platelet aggregability and platelet free calcium mobilisation in uraemic children: a possible link? Thromb Haemostas 1990; 64:7-10.
18. Clyne N, Berglund B, Egberg N. Treatment with recombinant human erythropoietin induces a moderate rise in hematocrit and thrombin antithrombin in healthy subjects. Thromb Res 1995;79:125-9.
19. Viron B, Chamma F, Jaar B, Michel C, Mignon F. Thrombosis of angio-access in haemodialysed patients treated with human recombinant erythropoietin. Nephrol Dial Transplant 1997;12:368-70.
20. Jaar B, Denis A, Viron B, Verdy E, Chamma F, Siohan P, Mignon F. Effects of long-term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation. Am J Nephrol 1997;17: 399-405.
21. Macdougall M, Davies ME, Hallet I, Cochlin DL, Hutton RD, Coles A, Williams JD. Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant 1991;6:862-7.
22. Sinasi O, Turkiz G. Von Willebrand factor and rise in ristocetin co-factor with erythropoietin. Lancet 1993;341:1221.
23. Churchill DN, Muirhead N, Goldstein M, Posen G, Fay W, Beecroft ML, et al. Probability of thrombosis of vascular access among haemodialysis patients treated with recombinant human erythropoietin. J Am Soc Nephrol 1994;4:1809-13.
24. Wiesholzer M, Kitwögerer M, Harm F, Barbieri G, Hauser AC, Prisbanig A, et al. Prevalence of preterminal pulmonary thromboembolism among patients on maintenance haemodialysis treatment before and after introduction of recombinant erythropoietin. Am J Kidney Dis 1999;33:702-8.
25. Dale GL, Alberio L. Is there a correlation between raised erythropoietin and thrombotic events in sickle-cell anaemia? Lancet 1998;352: 566-7.
26. Salvati F, Liani M. Erythropoietin and thrombotic events. Lancet 1998;352:1471.
27. Sayinalp N, Erdem Y, Ozcebe OI, Büyükasik Y, Caglar S, Dündar SV. Recombinant human erythropoietin increases platelet aggregation in chronic haemodialysis patients. Thromb Res 1998;90:195-8.
28. Cases A, Escolar G, Reverter JC, Ordinas A, Lopez-Pedret J, Revert L, et al. Recombinant human erythropoietin treatment improves platelet function in uremic patients. Kidney Int 1992;42: 668-72.
29. Taylor JE, Henderson IS, Stewart WK, Belch JJF. Erythropoietin and spontaneous platelet aggregation in haemodialysis patients. Lancet 1991;338:1361-2.
30. Taylor JE, Belch JJF, Henderson IS, Stewart WK. Erythropoietin does not increase whole-blood platelet aggregation in vitro. Nephrol Dial Transplant 1993;8:1291-3.
31. El-Shahawy MA, Francis R, Akmal M, Massry SG. Recombinant human erythropoietin shortens the bleeding time and corrects the abnormal platelet aggregation in haemodialysis patients. Clin Nephrol 1994;41:308-13.
32. Small M, Lowe GDO, Cameron E, Forbes CD. Contribution of the haematocrit to the bleeding time. Haemostasis 1983;13:379-84.
33. Casadevall N, Dupuy E, Molho-Sabatier P, Tobelem G, Varet B, Mayeux P. Brief report: auto-antibodies against erythropoietin in a patient with pure red-cell aplasia. N Engl J Med 1996;334:630-3.